drugset / Trial / NCT03873038
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
RandomizedSequentialTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).
Timeline
- Start
- 2019-04-29
- Primary completion
- 2021-12-20
- Completion
- 2021-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-2060 | Monoclonal antibody | 8 mg | Intravenous |
| Subject | MK-2060 | Monoclonal antibody | 20 mg | Intravenous |
| Subject | MK-2060 | Monoclonal antibody | 25 mg | Intravenous |
| Subject | MK-2060 | Monoclonal antibody | 40 mg | Intravenous |